logo
  

Royalty Pharma Reaches $2.025 Bln Strategic Funding Partnership With MorphoSys

Royalty Pharma plc (RPRX) said that it has reached a $2.025 billion strategic funding partnership with MorphoSys AG (MOR), as part of MorphoSys' $1.7 billion acquisition of Constellation Pharmaceuticals (CNST).

It is expected that the partnership will fuel the expansion of the combined company's capabilities to help enable the development and potential approvals of important cancer treatments.

The funding partnership is anchored by Royalty Pharma's acquisition of MorphoSys' rights to receive future royalties on Janssen's Tremfya (guselkumab).

Tremfya is an anti interleukin (IL)-23, approved for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis and is also in clinical development for ulcerative colitis and Crohn's disease.

Royalty Pharma will also acquire the rights to receive royalties and certain milestone payments on four development-stage therapies.

Royalty Pharma will purchase the rights to receive 60% of MorphoSys' future royalties on gantenerumab. Gantenerumab, an anti-amyloid-beta monoclonal antibody, is in Phase 3 development for Alzheimer's disease by Roche.

Royalty Pharma will purchase the rights to receive 80% of MorphoSys' future royalties and 100% of its future milestones on otilimab. Otilimab, a fully human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GMCSF), is in Phase 3 development for rheumatoid arthritis by GlaxoSmithKline.

Royalty Pharma will buy the rights to receive 3% of future net sales of pelabresib. Pelabresib, a bromodomain and extra-terminal (BET) inhibitor for myelofibrosis, is in phase 3 development by Constellation.

Royalty Pharma will purchase the rights to receive 3% of future net sales of CPI-0209. CPI-0209, a second-generation enhancer of zeste homolog 2 (EZH2) inhibitor, is in phase 2 development for hematological malignancies and solid tumors by Constellation.

The transaction is contingent on the closing of MorphoSys' acquisition of Constellation, which is expected in the third quarter of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ward Hill, Massachusetts-based Cedar's Mediterranean Foods is recalling Cedar's Organic Mediterranean Hommus citing undeclared pine nut, an allergen, the U.S. Food and Drug Administration said. The Cedar's Organic Mediterranean Hommus is packaged in a 10 oz. plastic container, with a UPC Code: 044115403028. Shares of UBS Group AG were gaining around 2 percent in Swiss trading after the banking major reported Tuesday higher profit in its third quarter with growth in net interest income. Further, the company said it intends to repurchase up to $0.6 billion of shares during the fourth quarter. The company will provide strategic update on February 1, 2022. HSBC Holdings Plc shares were gaining In London trading as well as in pre-market activity on the NYSE after the Asia-focused lender backed its positive outlook after reporting significantly higher third-quarter profit. Further, the company announced share buyback of $2 billion, which will be commenced shortly.
Follow RTT